Arcutis Biotherapeutics (ARQT) Invested Capital: 2020-2025
Historic Invested Capital for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $266.6 million.
- Arcutis Biotherapeutics' Invested Capital fell 26.21% to $266.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $266.6 million, marking a year-over-year decrease of 26.21%. This contributed to the annual value of $264.7 million for FY2024, which is 8.86% down from last year.
- Latest data reveals that Arcutis Biotherapeutics reported Invested Capital of $266.6 million as of Q3 2025, which was up 7.91% from $247.0 million recorded in Q2 2025.
- In the past 5 years, Arcutis Biotherapeutics' Invested Capital ranged from a high of $467.5 million in Q3 2022 and a low of $247.0 million during Q2 2025.
- Its 3-year average for Invested Capital is $305.9 million, with a median of $280.3 million in 2023.
- Per our database at Business Quant, Arcutis Biotherapeutics' Invested Capital skyrocketed by 109.74% in 2021 and then slumped by 47.06% in 2023.
- Arcutis Biotherapeutics' Invested Capital (Quarterly) stood at $370.0 million in 2021, then rose by 10.09% to $407.4 million in 2022, then decreased by 28.69% to $290.5 million in 2023, then decreased by 8.86% to $264.7 million in 2024, then declined by 26.21% to $266.6 million in 2025.
- Its Invested Capital was $266.6 million in Q3 2025, compared to $247.0 million in Q2 2025 and $250.3 million in Q1 2025.